Posts: 3,675,934
Threads: 734,342
Joined:
Sep 2021
Reputation:
5
All but which of the following statements about graft-versus-host disease (GVHD) are true?
A. Up to 50% of patients surviving more than 6 months after allogeneic transplantation develop
chronic GVHD.
B. T cell depletion is associated decreased GVHD and improvement in cure rates.
C. GVHD is more common in recipients from unrelated donors than in recipients from matched
siblings.
D. Sicca syndrome is a common manifestation of chronic GVHD.
E. Acute GVHD typically manifests with an erythematous maculopapular rash, persistent
diarrhea, or elevations in transaminases
Posts: 3,675,934
Threads: 734,342
Joined:
Sep 2021
Reputation:
5
B ... I think T cell excess causes graft improvement
no clue abt A.
certaibly c, d and e are true....
Posts: 3,675,934
Threads: 734,342
Joined:
Sep 2021
Reputation:
5
whats the quest. true or not true
Posts: 3,675,934
Threads: 734,342
Joined:
Sep 2021
Reputation:
5
The answer is B.
GVHD results from allogeneic T cells that transferred with the donor's stem cells reacted with
antigenic targets on host cells. Acute GVHD is defined as developing within the first 3 months
after a transplant. Acute GVHD is manifested clinically by a rash, persistent anorexia or
diarrhea, and liver disease with increased serum levels of bilirubin, transaminases, and alkaline
phosphatase. Biopsy is required for confirmation. The grade of GVHD predicts the prognosis.
Recipients from unrelated donors have a much higher rate of GVHD than do matched siblings.
This accounts for the much higher mortality from unrelated donor transplants. Depletion of T
cells from the donor results in a lower incidence of GVHD. However, it also results in a higher
relapse rate, and there is no evidence that this approach improves cure rates in any specific
setting. Chronic GVHD occurs in up to 50% of patients who survive more than 6 months after
an allogeneic bone marrow transplantation. This disease resembles an autoimmune disorder,
with malar rash, sicca syndrome, arthritis, obliterative bronchiolitis, and bile duct degeneration
and cholestasis. In most patients chronic GVHD resolves, but it may require years of
immunosuppressive treatment before these agents can be withdrawn without disease
recurrence.
